Metabolic support with perhexiline for myocardium protection in patients undergoing coronary artery surgery.
Phase of Trial: Phase II/III
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Perhexiline (Primary)
- Indications Myocardial ischaemia; Myocardial reperfusion injury
- Focus Therapeutic Use
- Acronyms CASPER
- 16 Sep 2015 Subgroup results (stereoselective handling of perhexiline) published in the European Journal of Clinical Pharmacology.
- 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
- 20 May 2010 Planned end date changed from 29 Jan 2010 to 13 Apr 2010 as reported by United Kingdom Clinical Research Network record.